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Sllmmar~ 
The effect of Bcl-xL upon the developmental death of T cells was assessed by generating trans- 
genic mice that expressed Bcl-xL within all thymocyte subsets. Bcl-xL protected thymocytes from 
a variety of apoptotic stimuli, including 3' irradiation, glucocorticoids, and anti-CD3 treatment. 
Bcl-xL altered thymocyte maturation, resulting in increased numbers of CD3  int/hi and CD4- 8 + 
thymocytes. Overall,  the phenotype of Bcl-xL transgenics was essentially indistinguishable from 
a Bcl-2 transgenic model. Overexpression of Bcl-xL or Bcl-2 resulted in the down-regnlation 
of the other molecule, providing further evidence of their reciprocal  regulation. In a genetic 
test of redundancy, the Bcl-xL transgene rescued mature T  cells in Bcl-2 null mice. Immuno- 
precipitation indicated that Bcl-xL, like Bcl-2, heterodimerized with the death-promoting mol- 
ecule Bax in thymocytes. This in vivo model argues that Bcl-xL, like Bcl-2,  functions in a 
common pathway to repress cell death. 
R 
gnlated cell death is indispensable for the proper dif- 
ferentiation and maintenance of homeostasis in mul- 
tiple lineages. The creation of a functional immune system 
is particularly dependent upon the selective survival and apop- 
totic demise of specific cells during lymphocyte maturation 
(1, 2). The susceptibility to death for a developing lympho- 
cyte after the same stimulus varies markedly at different stages 
of development. Bcl-2 is one molecule that helps to deter- 
mine the cell-autonomous susceptibility to apoptosis. For ex- 
ample, mature CD4 or CD8 single-positive (SP)  1 medullary 
thymocytes are resistant to apoptotic signals and possess high 
levels of the death repressor molecule, Bcl-2. In contrast, the 
CD4+8 + double-positive (DP) cortical thymocytes lack Bcl-2 
and are highly vulnerable to a wide variety of apoptotic stimuli 
(3,  4). 
Recently, an expanding family of Bcl-2 homologues has 
been identified. They share homology that is principally, but 
not exclusively, clustered within two conserved domains, en- 
titled Bcl-2 homology 1 and 2 (BH1 and BH2) (5, 6). This 
includes Bax, which heterodimerizes with Bd-2 and counters 
its activity.  The ratio of Bcl-2/Bax can determine whether 
a given cell will execute or ignore an apoptotic stimulus (7). 
Single-amino acid substitutions within the BH1 or BH2 do- 
1 Abbreviations used in this paper:. BH1, Bcl-2 homology 1; BH2, Bcl-2 ho- 
mology 2; DN, double negative; DP, double positive; SP, single positive. 
main of Bcl-2 disrupted Bcl-2/Bax heterodimers, but not Bcl- 
2/Bcl-2 homodimers. Bcl-2 mutants that were unable to het- 
erodimerize with Bax no longer inhibited apoptosis (6). This 
indicates  that this family possesses both positive and nega- 
tive regulators of death and that these proteins function at 
least  in part through protein-protein interactions. 
Given the existence of one regulatory pair, Bcl-2 and Bax, 
that can promote or repress apoptosis, an important ques- 
tion arises as to the rationale for further family members. 
An additional member, Bcl-x, has also been shown to regu- 
late apoptosis in cell lines (8). A long form, Bcl-xL, which 
possesses BH1 and BH2, will repress cell death. A short RNA 
species noted in humans, Bcl-xs, lacks the BH1 and BH2 do- 
mains and has been noted to counter the protective effect of 
Bcl-2.  It is of interest that species specificity in the alter- 
natively spliced product, Bcl-xs,  has been noted. Bcl-xs is 
readily detected in human but not in murine thymocytes, 
while Bcl-xL is present in the mouse thymus (9,  10). 
Prior studies of gain-of-function Bcl-2 transgenic mice noted 
effects of this death repressor upon both thymocyte survival 
and maturation. When Bcl-2 was uniformly expressed within 
all thymocytes including DP cells, it conferred resistance to 
glucocorticoids, 3' irradiation, and T cell-specific stimuli such 
as anti-CD3 treatment. However,  the levels of Bcl-2 were 
unable to block the negative selection deletion of thymocytes 
(11, 12). Subsequently, a Bcl-2 transgene was introduced into 
genetic models in which thymocyte maturation was blocked. 
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ot/fl TCR mice but had no effect on CD4 lineage matura- 
tion. Moreover, ct/fl TCR transgenic mice revealed that Bd-2 
was up-regulated at the CD4 +  8 + stage during positive se- 
lection (13). Studies with Bd-2-deficient mice have indicated 
that Bcl-2 is not solely required as a single member for the 
completion of T cell development. Instead, Bcl-2 -/-  mice 
are unable to maintain homeostasis demonstrating apoptotic 
loss of both lymphocyte lineages postnatally (14). 
To test whether Bd-xL would repress cell death in normal 
development and affect maturation,  we generated a Bcl-xr 
transgenic  model.  We  wished  to  explore  whether  Bcl-xL 
functions through a separate pathway or impacts a common 
pathway shared with Bcl-2. To compare the effects of Bcl-xL 
with  those  of Bcl-2,  we  generated  mice  using  the  same 
lck proximal promoter to express transgenic Bd-xL. Despite 
the alternating normal pattern of expression of Bd-2 and Bcl- 
XL in  the  thymus  (3,  10,  15),  the  phenotype  of gain-of- 
function Bcl-xL transgenics was remarkably similar to Bcl-2 
transgenics.  Moreover, both repressor molecules heterodimer- 
ized with Bax in vivo. These in vivo data favor a model in 
which Bcl-xt and Bcl-2 function in a common pathway to 
regulate cell death. 
Materials  and Methods 
Mice.  A 0.8-kb cDNA of human Bcl-xL (8) was inserted into 
the lck-hGH vector (16) to generate the ttansgenic animals as pre- 
viously  described  (11). kkpr-bcl-xL transgenic  mice bred  on  the 
C57BL6/J background were maintained in a pathogen-free animal 
facility at Washington University (St. Louis, MO). Bcl-2-deficient 
animals (14) were bred to lckpr-bcl-xt transgenic mice in the same 
facility. 
Cell Preparations.  Single-cell suspensions were made from lym- 
phoid organs after lysing red blood cells with Tris-NH4CI buffer 
and counted on a hemocytometer by trypan blue exclusion. Splenic 
T cells were purified by immunomagnetic  negative selection with 
anti-HSA, anti-B220, and anti-Mac-1 as previously described (13). 
The purity of splenic T cells was usually 85-90%, determined by 
anti-CD3  staining. 
Western Blot Analysis.  Single-cell suspensions were tysed in 150 
mM NaC1, 10 mM Tris, pH 7.4, and 1% Triton X-100 buffer. After 
quantitation  of the amount of protein using the Bradford method 
(17), 35 #g of protein was run in each lane of a 12.5% SDS-poly- 
acrylamide gel. Blots were developed with enhanced chemilumi- 
nescence (Amersham Corp.,  Arlington  Heights, IL) or diamino- 
benzidine. 
Antibodies.  The mAbs 3Fll (hamster IgG anti-murine  Bcl-2) 
and 4D2 (hamster IgG anti-murine Bax) were used as purified an- 
tibody prepared by protein A chromatography.  13.6 is a polyclonal 
antiserum (rabbit IgG) raised against human Bcl-x that cross-reacts 
with murine Bcl-x. 7B2 is an mAb recognizing human and mu- 
fine Bcl-x (murine IgG). The details of antibody production  are 
described elsewhere (18). All other mAbs used in this study were 
purchased from Pharmingen (San Diego, CA). Secondary antibodies 
were biotinylated goat anti-hamster  or anti-rabbit antibodies ob- 
tained from Caltag Laboratories (San Francisco, CA). 
Viability Assay.  Cells  were plated at 106 cells/ml in DME sup- 
plemented with 5% FCS (GIBCO BRL, Gaithersburg, MD). At 
each time point,  the cells were collected and viability was deter- 
mined by propidium  iodide exclusion. 
In Vivo Anti-CD3 Injection.  50 ~g of aflfinity-purified anti-CD3 
(done 2Cll; Pharmingen  Inc.) or vehicle control  (PBS) was in- 
jected intraperitoneaUy into  8-12-wk-old  transgenic and control 
littermates. Thymi were removed 48 h after treatment.  Single-cell 
suspensions were made in cold medium and stained for surface CD4 
and CD8 within 2 h. 
Imraunoprecipitation.  Fresh thymocytes were washed twice in 
serum-free,  methionine-free  DME  (GIBCO  BRL).  Metabolic 
labeling was then  performed  with 40/~Ci/ml  of Trans3SS-label 
(ICN Biomedicals, Inc., Costa Mesa, CA) for 3-4 h. Cells were 
harvested and lysed in an NP-40 isotonic lysis buffer with protease 
inhibitors (142.5 mM KC1, 5 mM MgC12, 10 mM Hepes, pH 7.2, 
0.25% NP-40) by nutation for 30 min in the cold room. Immuno- 
precipitation was performed as previously described (7). 3SS-labeled 
bands were quantitated  by Phosphorlmager  scanning (Molecular 
Dynamics,  Inc., Sunnyvale, CA). 
Results 
Generation ofTransgenic M/c~  A transgenic construct was 
created by inserting  the human lkl-xt cDNA downstream 
of the lck proximal promoter (16). The 3' untranslated por- 
tion of the construct possessed hGH exons, introns,  and a 
poly(A) addition site to ensure proper processing of the tran- 
script  (Fig.  1 A).  kkr-Bcl-xt  lines  I2  and  24,  which  ex- 
pressed high levels of BcI-xL, were propagated. The majority 
of experiments were done with the highest expressing line 
12 and confirmed with  line 24. 
Transgene expression was analyzed by Western blot and 
flow cytometry. Bcl-xL was highly expressed in both thymus 
and spleen. The purified splenic T cell subpopulation sho~ed 
a  marked  increase  in  Bcl-xt  (Fig.  1 B).  Flow cytometry 
using permeabilized thymocytes indicated that Bcl-xL levels 
were uniformly greater  in  transgenic  than  in  normal  thy- 
mocytes (Fig. 1 C). Three-color flow cytometric analysis re- 
vealed comparable levels of Bd-xL in double-negative (DN) 
(CD4-8-),  DP (CD4 + 8 +),  and CD4 SP or CD8 SP thy- 
mocytes (data not  shown). 
Bcl-xL Alters  Thymocyte  Maturation.  All transgenic  ani- 
mals had an increase in CD3  int/hi and a reciprocal decrease 
in  CD31~ thymocytes  compared  with  control  littermates 
(Fig.  2 A). Parallel changes were seen in the t~/fl T cell sub- 
set  of transgenic  animals,  but  no  alteration  was found in 
3~/~ T  cells  (data not shown).  An increase in intermediate 
CD4 +  8  l~ and CD41~  + thymocytes, which represent a tran- 
sitional stage in thymic maturation, was also consistently noted 
in  transgenic  animals  (Fig.  2 B).  Moreo~r,  all  kkp'-bcl-xL 
mice had an increase in CD8 SP thymocytes, while some also 
displayed an increase in the CD4 cells (Fig.  2 B, Table 1). 
Although overexpression of Bcl-xL did not substantially in- 
crease the total number of thymocytes, it altered the distri- 
bution of T cell subsets (Table 1). The ratio of CD4 to CD8 
SP thymocytes was skewed to  1.9 in transgenic  versus 3.5 
in control mice. In addition, the total number of splenic lym- 
phocytes was uniformly higher  in Bcl-xL transgenic  mice. 
The absolute number of B cells was unchanged.  Flow cyto- 
metric analysis  demonstrated  an increase in T  cells as well 
as an increased percentage of CD8 SP cells in the spleen of 
the transgenics (Fig. 2 C). Thus, constitutive overexpression 
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Figure  1.  Bcl-xL  construct and expression analysis. (.4) The human 
Bcl-xg cDNA was inserted at the BamHI site under the control of lck 
proximal promoter  (17). Hatched boxes in the  3'  untranslated region 
represents the exons of the human growth hormone (hGH) gene. (B) 
Western blot analysis of transgene expression￿9  Cell lysates were prepared 
from single-call  suspensions  of  thymus  or spleen.  Splenic  T cells  were  purified 
using negative selection with immunomagnetic beads. 35/~g of protein 
lysate from transgenic line 12 or wild-type (wt) cells was loaded in each 
lane. The anti-Bcl-xL  polyclonal  antibody 13.6 was used to detect the pres- 
ence of both the endogenous murine and the human transgenic Bcl-xL 
proteins. The immunoblot was developed  with diaminobenzidine.  (C) Flow 
cytometry histogram quantifying the Bcl-xg  protein in permeabilized  thy- 
mocytes from wild-type and kker-bcl.xL  trausgenic (Tg) mice stained with 
the 7B2 anti-Bcl-x mAb. 
of Bcl-xL altered thymocyte maturation in a pattern similar 
to that of Bcl-2 transgenic mice (11),  resulting in a marked 
excess of CD8  SP cells. 
Prolonged Survival of ~ansgenic Thymocytes.  We next asked 
whether  Bcl-xL  altered  the  survival  and  susceptibility  of 
thymocytes to apoptosis.  Since we had previously generated 
Bcl-2 transgenic mice using the same promoter, we were able 
to compare the effects of Bcl-xL and Bd-2 on thyrnocyte cell 
death.  Thymocyte suspensions  from  kkpr-bcl-2, kkpr-bcl-xr, 
and wild-type littermates were plated in 5% FCS (Fig. 3 A). 
After 100 h, 80%  of both Bcl-xr and Bcl-2 transgenic thy- 
Figure  2.  Bd-xt alters thymocyte maturation. (A) Single-cell  suspen- 
sions of thymocytes from 5-wk-old wild-type (Wt) and tckc'-bd-xL  trans- 
genic mice were stained with FITC-conjugated anti-CD3 mAb. The per- 
centages of CD3"~g, CD31~ CD3  int/hi cells are indicated at the top of the 
histograms. (B) Flow cytometric analysis of thymocytes, and (C) CD3- 
gated splenic T cells from wild-type and transgenic animals for CD4 and 
CD8 expression. The percentages of each subset are shown at the right 
upper corner of each quadrant. 
mocytes were viable, whereas <10%  of the normal thymo- 
cytes survived. Similarly, splenic T cells from both transgenics 
also  revealed improved  survival in vitro  (data  not  shown). 
The survival between Bcl-xL- and Bcl-2-expressing thymo- 
cytes or splenic T  cells was  similar. 
Bcl-xt Protects Thymocytes from Glucocorticoid and Radiation- 
induced Apoptosis.  The protective ability of overexpression 
of Bd-xg to several different apoptotic stimuli in thymocytes 
was tested. Both glucocorticoid treatment and low-dose ir- 
radiation are known to cause a rapid depletion of immature 
thymocytes by apoptosis. Thus, thymocytes were treated ei- 
ther with  100 nM dexamethasone (Fig. 3 B) or 225 tad of 
"y irradiation (Fig. 3 C). By 48 h, most of the normal thymo- 
cytes were  dead,  whereas  50-60%  of either  kkt"-bcl-xt  or 
kk~-bcl-2 thymocytes were still viable (Fig. 3 C).  The trans- 
genic thymocytes were resistant to anti-Fas Ab treatment in 
a  similar  matter  (data  not  shown). 
lcke,-bcl-xL Thymocytes  Are Resistant  to Anti-CD3-induced 
Apoptosis  In  Viva  To  assess  whether  Bcl-xL was  able  to 
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Transgenic  Wild type 
Total thymocytes 
(￿  lO  6) 
Splenic T  cells  (x  10  6) 
CD4 
93.5  _+  35.4 
27.1  _+  8.8 
CD8  CD4/CD8  ratio  CD4 
77.4  +_  35.1 
9.8  +_  2.5 
CD8  CD4/CD8  ratio 
Percentage of total 
thymocytes 
Percentage of total 
splenic cells 
16.1  _+  5.7  9.8  _+  4.6  1.9  +  0.7 
26.3  _+  7.4  15.4  _+  4.3  1.7  _+  0.5 
10.4  _+  3.3  3.4  _+  1.2  3.5  _+  1.8 
21.7  +_  6.4  8.9  _+  2.8  2.5  _+  0.3 
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Figure  3.  Bcl-xL  prolongs  thymocyte  survival in vitro and protects 
from gluc~orticoid and 3' irradiatien-indurx~l al~ptosis. Thym~:ytes from 
wild-type (ll), kl~.kl-xt  ([]), and kk.~-bcl-2 (0)  mice were plated at 
106 cells/ml in DMEM with 5% PCS (A), with 100 nM de~methasone 
(B), or with 225 lad 3" irradiation (C). Cell viability was determined by 
propidium iodide exclusion. 
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Figure 4.  Anti-CD3 induced apoptosis. Total thymocytes from 12-wk- 
old mice were analyzed 48 h after in vivo injection of (A) PBS or (B) 
anti-CD3 mAb for cell number (in parenthesis) and thymocyte subsets by 
surface CD4 and CDS. (C) Combined data from a total of six indepen- 
dent experiments and >10 mice in each category (ages 8-12 wk old). Each 
experiment compares transgenics  with littermate controls as wild type (Wt). 
Plotted values represent the percentages of thymocytes remaining after in 
vivo treatment with anti-CD3 Ab, in which 100% represents the average 
thymocyte number after treatment with PBS. 
824  Bcl-xL  Substitutes for Bcl-2 In Vivo block a T  cell-specific apoptotic signal, an anti-CD3 mAb 
was injected intraperitoneaUy into transgenic mice and con- 
trol littermates. 48 h after treatment, thymi were harvested 
and compared with mice treated with PBS alone (Fig. 4 A). 
After anti-CD3 administration, the number of DP thymo- 
cytes was decreased substantially (90%) in wild-type animals. 
However, kkv'-bcl-xt mice were resistant to in vivo anti-CD3 
treatment in the DP population (Fig. 4 B). While the extent 
of protection varied, all transgenic mice had substantially more 
thymocytes after in vivo anti-CD3 treatment compared with 
their wild-type littermates in six independent experiments 
(Fig.  4  C). 
Reciprocal Down-regulation of Endogenous Bcl-xL and Bcl-2. 
A  previous report had shown that endogenous Bcl-2  was 
down-regulated in the B cells of animals bearing the Bcl-2-Ig 
transgene (19). A  similar down-regulation of endogenous 
Bcl-2 was also observed in lck~-bcl-2 transgenic mice using 
3Fll, an mAb specific for mouse Bd-2 (Fig.  5). It is note- 
worthy that,  in both  the thymocytes and  splenic  T  cells 
of lckp:bcl-xL mice, the endogenous Bcl-2 (3Fll mAb) pro- 
tein expression was down-regulated. In parallel, endogenous 
Bd-xr (13.6 Ab) expression was also decreased in the thymo- 
cytes of kkp'-bcl-2 animals (Fig. 5). The minimal amount of 
Bcl-xL in splenic T cells was also suppressed in the kker-bcl-2 
animals. We were unable to determine if endogenous Bcl-xt 
was  down-regulated in  Bd-xL  transgenic mice  since  the 
polyclonal  Ab  13.6  recognizes both  human  and  murine 
Bcl-xL. The reciprocal relationship of Bcl-2 and Bcl-xL pro- 
tein levels suggests that their regulation may be coordinated 
in an inverse fashion. 
Bcl-xL Rescues Bcl-2-deficient Cells.  The  phenotype of 
the Bcl-xL gain-of-function transgenics was similar to that 
of comparable Bcl-2  transgenics.  Consequently, we tested 
whether Bcl-xg would substitute for Bcl-2 in vivo. kt#r-bcl-xL 
transgenics were mated to  Bcl-2-deficient mice to  deter- 
mine whether selective expression  of Bcl-xg would reverse 
the apoptotic loss of T  cells in Bcl-2 null mice. Analysis of 
peripheral lymphocyte populations in healthy-appearing  Bcl- 
2-/-  mice revealed loss of both B and T  cell populations 
(Fig. 6). In contrast, Ick~-bcl-xL/Bd-2-/-  mice displayed a 
comparable loss of B cells but retained normal to increased 
numbers of splenic T cells (Fig. 6). In a total of six indepen- 
dent experiments (mice aged 4-7 wk),  all kkv'-kl-xL/Bcl- 
2-/-  mice had normalized peripheral T  cell populations 
when  compared with  their  Bd-2-/-  littermates.  Thus, 
Bcl-xL was able  to rescue  total  splenic  T  cell numbers in 
Bcl-2-deficient mice. 
Bcl-xL Represses Cell Death in Bcl-2-deficient Thymocytes. 
Thymocytes from Bcl-2-deficient mice demonstrate acceler- 
ated cell death after an apoptotic stimulus (14). We compared 
the sensitivity to apoptosis of thymocytes from Bcl-2-/- 
and k~-bcl-xL/Bd-2-/-  mice. Thymocytes plated in media 
with 5%  FCS displayed increased  survival  for Ickz-bcl-xL/ 
Bcl-2-/-  cells compared with littermate Bcl-2-/-  cells 
(75% vs 45% at 24 h) (Fig. 7 A). In addition, thymocytes 
from kkzr-bcl-xt/Bcl-2-/-  mice were more resistant  to 100 
nM dexamethasone (Fig. 7 B), and 225 tad of 3' irradiation 
Figure  5.  Down-regulation of endogenous Bcl-xL  and Bcl-2. Western 
blot analysis of Bd-xt (13.6 Ab) and murine Bd-2 (3Fll mAb) in thymo- 
cytes and splenic T cells from kk.~-kl.2,  wild-type (wt), and kka"-bcl-xL 
animals. The 13.6 polyclonal antibody recognizes both human and mu- 
fine Bcl-x. The 3Fll mAb recognizes the endogenous murine Bcl-2 but 
not the transgene origin human Bcl-2. 
(Fig. 7 C) than Bcl-2-deficient cells. Therefore, Bcl-xL was 
able to restore viability and repress apoptosis after multiple 
stimuli in cells lacking Bcl-2. 
Bcl-xL Also Heterodimerizes  with Bax In Viva  Since Bcl-xL 
would  substitute  for  Bcl-2  in  countering cell  death,  we 
gxplored whether they both function in a common pathway. 
Bcl-2 heterodimerizes with a homologue Bax, which pro- 
motes cell death (7). Consequently, we examined thymocytes 
from normal and lckVr-bcl-xt transgenic mice to determine 
whether Bcl-xt associates with Bax (Fig. 8). Normal thymo- 
cytes, when radiolabeled  and immunoprecipitated with an 
anti-Bcl-x antibody, revealed moderate amounts of Bd-xL 
and some associated Bax (Fig. 8 A). It is of potential interest 
that several other bands were also seen (Fig. 8 A). However, 
only a minority of the total amount of Bax in normal thymo- 
cytes was heterodimerized with Bd-xL. In Bd-xg transgenic 
mice, however, immunoprecipitation of Bd-xg coprecipitated 
substantial portions of endogenous  Bax (Fig. 8 A). Moreover, 
immunoprecipitation of Bax demonstrates considerable het- 
erodimerizing Bcl-xL (Fig.  8 B).  Phosphorlmager analysis 
of primary and secondary immunoprecipitates  indicates that, 
in thymocytes from normal control mice, only 30% of Bax 
is heterodimerized with Bd-xg (Fig. 8 A, upper~nel), while 
the supernatant of that immunodepletion reveals that 70% 
of Bax is unbound (Fig.  8 A,  lower  panel).  In contrast, in 
the presence  of the Bcl-xL transgene, a substantial portion 
of Bax (77%)  is heterodimerized with Bd-xg, while only 
23% of Bax is unbound (Fig. 8 B). The heterodimerization 
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Figure 6.  Bcl-xL  substitutes for Bcl-2 function 
in vivo. (A) Flow cytometric  analysis of spleen 
mononuclear cells from  representative,  healthy 
7-wk-old mice. Total spleen cell numbers of each 
animal are shown in parenthesis under each panel. 
Numbers indicating the percentages of total spleen 
cells that were B (B220+) or T (CD3 +) cells are 
shown next to the boxed populations. (B) Graphic 
presentation of the absolute number (in millions) 
of splenic T (closed bar) and B cells (open bar) from 
representative littermate mice at 7 wk of age. 
of >50%  of Bax with either Bcl-2  or Bcl-xL resulted in 
repression of cell death in a cell line system (20). Thus, trans- 
genic Bd-xL as well as Bcl-2 displays substantial heterodi- 
merization in vivo with the death-promoting molecule Bax. 
Discussion 
We generated a gain-of-function transgenic model to de- 
termine whether Bcl-xL, which has been shown to block 
apoptosis within certain cell lines  (8), would alter normal 
developmental cell death within an animal model. Overex- 
pressed Bcl-xL in normal thymocytes inhibited cell death 
after dexamethasone, 3' irradiation, and anti-CD3 treatment. 
Moreover, lineage-specific expression of Bd-xt altered T cell 
maturation. Increased populations of CD3  int/hi thymocytes 
and intermediate CD4+81~ and CD41~  cells in transition 
to becoming SP cells were noted. In addition, a skew to CD8 
cells was noted both in the thymus and the periphery. The 
overall  phenotype of the  lckp'-bcl-xL  transgenic  mice was 
nearly indistinguishable from that of Ickt"-bcl-2  transgenics 
generated with the same promoter (11). Detailed studies of 
Bcl-2 transgenics indicated that Bcl-2 was able to promote 
maturation in the absence of critical signals (13). This Bcl-xL 
model strengthens the argument that repressing apoptosis 
may enable differentiation irrespective  of the specific mole- 
cule that inhibits the death pathway. 
Recently, there has been a marked expansion in the number 
of Bcl-2 family members. This has raised important ques- 
tions as to whether each molecule has an entirely distinct 
function or whether they all regulate a common pathway. 
The similarity of Bcl-2 and Bcl-xL transgenics suggests that 
these two molecules, which both repress cell death, might 
be interchangeable. The selective introduction of Bcl-xL into 
the T cells of Bcl-2-deficient mice restored resistance to apop- 
totic stimuli and rescued mature T  cell populations. This 
rigorously established that Bcl-xL could substitute for Bcl-2 
in maintaining T  cell homeostasis. Since the Bcl-xt trans- 
gene was only expressed in T  cells, the capacity for Bcl-xt 
to replace Bcl-2 in B cells was not assessed. However,  the 
normal physiologic roles of Bcl-2 and Bcl-xL could prove to 
be distinct. Bcl-2 displays an on-off-on pattern of expression 
during T cell development. The most immature DN thymo- 
cytes possess Bcl-2, which is down-regulated at the DP stage. 
Bcl-2 is subsequently reexpressed during positive selection, 
and the protein remains high in mature CD4 and CD8 thymo- 
cytes (3,  13). In contrast, Bcl-x is principally expressed in 
the cortex and not the medulla (15). Only minimal amounts 
of Bcl-xr  are found in DN thymocytes, but DP cells have 
high amounts of Bcl-xL. Bd-xL is no longer expressed in SP 
thymocytes or peripheral T cells (10). However, it is Bcl-xL, 
but not Bcl-2, that responds to activation being reexpressed 
in mature T cells after TCR engagement (18). It is noteworthy 
that both Bcl-2 and Bcl-xL transgenic mice demonstrated a 
reciprocal down-regulation of the other member. This pat- 
tern of regulation is consistent with a sensing mechanism 
that would help coordinate the alternating patterns of Bcl-2 
and Bcl-xL expression  during development. This example 
emphasizes that homologues that display functional redun- 
dancy in genetic complementation tests may normally have 
slightly different physiologic roles,  thereby accounting for 
their comaintenance during evolution. 
The serial, alternating pattern of Bcl-2 and Bcl-xL expres- 
sion and the fact that each gain-of-function model appeared 
essentially identical suggested that both Bcl-2 and Bcl-xL im- 
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Figure 7.  Bcl-xt restores resistance to  apoptotic stimuli in  Bcl- 
2-deficient  thymocytes.  Fresh thymocytes  from Bcl-2 -/-  (11) and kkz- 
bcl-xL/Bd-2-/-  mice (O) were plated at 106 cells/ml in DMEM with 
5% FCS (.4). In/3, thymocytes  were  treated  with 100 nM dexamethasone, 
and, in C, with 225 rad 3' irradiation. A representative  of four indepen- 
dent experiments  is shown. Animals used in this experiment  were  6-wk- 
old littermates. 
pact a common pathway.  The emerging Bcl-2 gene family 
shares its principal homology within two conserved domains 
entitled BH1 and BH2 (5). Bcl-2 is known to heterodimerize 
with a death-promoting family member, Bax (7). Mutagen- 
esis analysis of Bd-2 indicated that BH1 and BH2 are novel 
domains that regulate heterodimerization. Point mutations 
within BH1 and BH2 argue that Bd-2 must heterodimerize 
with  Bax to repress death  (6).  Consequently, we assessed 
Figure 8.  Heterodimerization  of Bd-xr with Bax in thymocytes.  (A, 
ufrper~nel ) Radiohbeled  thymocytes  from wild-type  (lane 1  ) or kk~-bcl-xt. 
mice (lane  2) were immunoprecipitated  with anti-Bcl-x  (13.6) polyclonal 
antibody. A Western blot of this immunoprecipitate  confirmed  that the 
21-kD species  was Bax (data not shown). (7t, l~noer~nel) The remaining 
supematant from the immunodepletion of Bcl-xL shown in the upper 
panel underwent a secondary  immunoprecipitation  with the 4D2 anti- 
Bax mAb to assess the residual amount of Bax not heterodimerized  with 
Bcl-xt. (B) A primary  immunoprecipitation  of the same radiolabeled  thy- 
mocytes  with a polydonal  anti-Bax  Ab (10519) that recognizes  either  Bax 
homo or heterodimers. 
whether Bcl-xL would heterodimerize with Bax in vivo as 
part of their common effects.  In normal thymocytes, only 
a minority of  Bax (30%) was heterodimerized  with the modest 
levels of Bcl-xL. However, transgenic levels of Bd-xr resulted 
in the majority of Bax (77%) being heterodimerized with 
Bcl-xt.  In  a separate study using a cell line, various levels 
of Bcl-2, Bcl-xL, Bad, and Bax were rigorously quantitated 
and correlated with the susceptibility to apoptosis.  When 
'~50%  or more of the Bax in FL5.12 cells was complexed 
in heterodimers, apoptosis was suppressed after IL-3 depriva- 
tion (20). Thus, the difference in the percentage of Bax found 
in heterodimers with Bcl-xL within these transgenics is pre- 
dicted to be functionally significant. The capacity of Bcl-xL 
to mimic Bd-2 and substitute for it in repressing T cell death 
may relate to its ability to heterodimerize with a substantial 
portion of Bax. However, only a minority of native Bax (30%) 
is associated with Bcl-xt in normal thymocytes. It is possible 
that other bands noted in the anti-Bcl-xr immunoprecipi- 
tate might  represent independent partners for Bcl-xL that 
may also prove biologically significant in normal development. 
The alternative death  repressor molecules of Bcl-2 and 
Bcl-xt  appear  to  sequentially regulate  cell  death  at  serial 
stages of T cell development. These studies of transgenic mice 
indicate that Bcl-xL and Bcl-2 can repress cell death through 
a common pathway in which their interaction with Bax is 
one shared parameter. 
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